Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services
- PMID: 15660015
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services
Abstract
The most effective means of preventing human immunodeficiency virus (HIV) infection is preventing exposure. The provision of antiretroviral drugs to prevent HIV infection after unanticipated sexual or injection-drug--use exposure might be beneficial. The U.S. Department of Health and Human Services (DHHS) Working Group on Nonoccupational Postexposure Prophylaxis (nPEP) made the following recommendations for the United States. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person known to be HIV infected, when that exposure represents a substantial risk for transmission, a 28-day course of highly active antiretroviral therapy (HAART) is recommended. Antiretroviral medications should be initiated as soon as possible after exposure. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person of unknown HIV status, when such exposure would represent a substantial risk for transmission if the source were HIV infected, no recommendations are made for the use of nPEP. Clinicians should evaluate risks and benefits of nPEP on a case-by-case basis. For persons with exposure histories that represent no substantial risk for HIV transmission or who seek care >72 hours after exposure, DHHS does not recommend the use of nPEP. Clinicians might consider prescribing nPEP for exposures conferring a serious risk for transmission, even if the person seeks care >72 hours after exposure if, in their judgment, the diminished potential benefit of nPEP outweighs the risks for transmission and adverse events. For all exposures, other health risks resulting from the exposure should be considered and prophylaxis administered when indicated. Risk-reduction counseling and indicated intervention services should be provided to reduce the risk for recurrent exposures.
Similar articles
-
Human immunodeficiency virus postexposure prophylaxis for adolescents and children.Pediatrics. 2001 Aug;108(2):E38. doi: 10.1542/peds.108.2.e38. Pediatrics. 2001. PMID: 11483848
-
Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016.MMWR Morb Mortal Wkly Rep. 2016 May 6;65(17):458. doi: 10.15585/mmwr.mm6517a5. MMWR Morb Mortal Wkly Rep. 2016. PMID: 27149423
-
Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis.Clin Infect Dis. 2014 Jun;58(11):1618-24. doi: 10.1093/cid/ciu118. Epub 2014 Apr 10. Clin Infect Dis. 2014. PMID: 24723288
-
Postexposure prophylaxis: an intervention to prevent human immunodeficiency virus infection in adolescents.Curr Opin Pediatr. 2003 Aug;15(4):379-84. doi: 10.1097/00008480-200308000-00004. Curr Opin Pediatr. 2003. PMID: 12891049 Review.
-
Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus.Pediatrics. 2003 Jun;111(6 Pt 1):1475-89. doi: 10.1542/peds.111.6.1475. Pediatrics. 2003. PMID: 12777574 Review.
Cited by
-
Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.Open Forum Infect Dis. 2024 Jul 25;11(8):ofae436. doi: 10.1093/ofid/ofae436. eCollection 2024 Aug. Open Forum Infect Dis. 2024. PMID: 39139581 Free PMC article.
-
Missed Opportunities: A Narrative Review on Why Nonoccupational Postexposure Prophylaxis for HIV Is Underutilized.Open Forum Infect Dis. 2024 Jun 15;11(8):ofae332. doi: 10.1093/ofid/ofae332. eCollection 2024 Aug. Open Forum Infect Dis. 2024. PMID: 39086468 Free PMC article. Review.
-
Navigating Barriers and Opportunities: Perceptions of the Non-Occupational Post-Exposure Prophylaxis Care Continuum Among Young Sexual Minority Men, Aged 17-24, in the United States.AIDS Patient Care STDS. 2024 Jun;38(6):267-274. doi: 10.1089/apc.2024.0012. Epub 2024 Jun 12. AIDS Patient Care STDS. 2024. PMID: 38864761
-
Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies.Ann Med. 2023;55(2):2288309. doi: 10.1080/07853890.2023.2288309. Epub 2023 Dec 8. Ann Med. 2023. PMID: 38065681 Free PMC article.
-
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions.Lancet HIV. 2023 Dec;10(12):e816-e824. doi: 10.1016/S2352-3018(23)00238-2. Epub 2023 Nov 9. Lancet HIV. 2023. PMID: 37952551 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
